Children Prescribed Puberty Blockers Without Face-to-Face Consultations

The clinical pathway for gender-affirming care in minors typically involves a multidisciplinary assessment to ensure appropriate diagnosis and treatment. This process is designed to address the complex psychological and physiological considerations inherent in such interventions.¹

Investigation Findings

An investigation published in the BMJ in 2026 found that children were prescribed puberty blockers and cross-gender hormones without a face-to-face appointment.¹ The investigation identified cases where these treatments were initiated following assessments that did not include an in-person consultation.¹ The specific number of children affected and the duration over which these practices occurred were not detailed in the available abstract.¹ Similarly, the investigation did not specify the types of cross-gender hormones prescribed or the age range of the children involved.¹

The implications of prescribing such treatments without direct clinical interaction warrant consideration. Face-to-face appointments allow for a comprehensive physical examination, detailed psychological assessment, and direct observation of the patient, which are critical for informed decision-making in this patient population.¹ The absence of such an initial assessment may limit the clinician's ability to fully understand the patient's medical history, current mental health status, and social context.¹

Limitations and Context

The available information from the investigation is limited to the abstract, which does not provide granular data regarding the methodology, the specific clinics or practitioners involved, or the outcomes for the children who received treatment without face-to-face appointments.¹ The investigation's scope and the criteria used to identify cases of non-face-to-face prescribing are not elaborated.¹ Further details from the full paper would be necessary to understand the prevalence and specific circumstances surrounding these prescribing practices.¹

The ethical considerations surrounding remote prescribing for minors, particularly for interventions with significant and potentially irreversible effects like puberty blockers and cross-gender hormones, are substantial. Informed consent, a cornerstone of medical ethics, becomes more complex when direct interaction is absent. Clinicians rely on face-to-face consultations to assess a minor's capacity for consent, their understanding of the treatment's implications, and to identify any undue influence from external factors. The nuances of non-verbal communication, crucial for a holistic assessment of a child's psychological state and genuine desire for treatment, are entirely lost in a remote setting.

Furthermore, the long-term effects of puberty blockers and cross-gender hormones in minors are still an area of ongoing research. While these treatments are intended to alleviate gender dysphoria and provide time for further exploration of gender identity, their impact on bone density, fertility, and neurocognitive development requires careful monitoring. Without an initial face-to-face assessment, establishing a baseline for these critical health markers and ensuring consistent follow-up becomes significantly more challenging. This raises concerns about the potential for missed adverse events or inadequate management of side effects.

Regulatory and Guideline Adherence

Most national and international clinical guidelines for gender-affirming care in minors emphasize the importance of comprehensive, multidisciplinary assessments, often explicitly recommending in-person evaluations. For instance, guidelines from organizations such as the World Professional Association for Transgender Health (WPATH) and the Endocrine Society typically advocate for a thorough psychological and medical evaluation prior to initiating hormonal interventions. The findings of this BMJ investigation, even in abstract form, suggest a potential deviation from these established standards of care. Understanding the specific contexts in which these remote prescriptions occurred – whether due to geographical barriers, resource limitations, or other factors – is crucial for evaluating adherence to best practices and identifying areas for systemic improvement.

The implications extend beyond individual patient care to broader public health and regulatory frameworks. If remote prescribing of such sensitive treatments becomes a widespread practice without robust safeguards, it could erode public trust in gender-affirming care and potentially lead to calls for stricter regulation. Healthcare systems must balance accessibility to care with the imperative for safe, ethical, and evidence-based practice, especially when treating vulnerable populations like minors. Future research should aim to quantify the prevalence of such practices, explore the reasons behind them, and assess the outcomes for children who received care via these pathways, comparing them to those who underwent traditional face-to-face assessments. This would provide a more complete picture of the risks and benefits associated with different models of care delivery in this rapidly evolving field.